BiosciGen’s Post

Our latest paper describes a novel hybrid AI-structure-based approach to identify compounds that target both #G4 DNA structures and the #PARP1 enzyme, offering a promising new strategy for cancer therapy. Key to this breakthrough is our #PyRMD tool, an AI-powered solution that efficiently identified PARP1 inhibitors from vast chemical libraries, streamlining the drug discovery process. We've identified four dual-acting compounds, demonstrating significant antiproliferative activity, especially in cancer cells with DNA repair deficiencies. This breakthrough highlights the power of AI-driven drug discovery, exemplified by PyRMD, in developing innovative multi-target anticancer therapies. A big shout-out to Michele Roggia and Benito Natale for the effort put into this project! #DrugDiscovery #AI #DrugDesign #MedChem #cancerresearch #PyRMD Access the paper: https://lnkd.in/dYXRK532

⏰ TOMORROW: Don’t miss your opportunity to engage live with the principal curator behind COSMIC Actionability! Join us tomorrow, March 7 at 11 a.m. EST / 4 p.m. GMT for an exclusive interactive webinar featuring Dr. Steve Jupe, COSMIC Actionability's principal curator and Dr. Kyle Nilson, field software trainer at QIAGEN Digital Insights. In this webinar, you’ll explore a series of use cases demonstrating how #cancer and #biopharma labs like yours can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ➡️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations. ➡️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability. ➡️ Use mutational signatures for potential clinical diagnosis and drug development applications.   Hurry – there’s still time! Register now 👇 Can’t make it at this time? Don’t worry. Register now and we’ll send you the on-demand recording as soon as its available. #drugdevelopment #precisiononcology

⏰ TOMORROW: Don’t miss your opportunity to engage live with the principal curator behind COSMIC Actionability!   Join us tomorrow, March 7 at 11 a.m. EST / 4 p.m. GMT for an exclusive interactive webinar featuring Dr. Steve Jupe, COSMIC Actionability's principal curator and Dr. Kyle Nilson, field software trainer at QIAGEN Digital Insights. In this webinar, you’ll explore a series of use cases demonstrating how #cancer and #biopharma labs like yours can harness @Catalogue Of Somatic Mutations In Cancer (COSMIC), to:   ● Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations. ● Integrate variants with curated findings and summaries of mutational impact and clinical actionability. ● Use mutational signatures for potential clinical diagnosis and drug development applications.   Hurry—there’s still time, register now!   Can’t make it at this time? Don’t worry. Register now and we’ll send you the on-demand recording as soon as its available.   #drugdevelopment #precisiononcology https://lnkd.in/dfrPfgRx

Watch our panel of experts representing views from across #clinicalresearch, drug commercialization and clinical practice and discuss the state of #breastcancer care today and where it is headed, including: - How organizations across the healthcare industry are tackling complex clinical decision-making - The use of #AI to accelerate breast cancer research and clinical practice - Treatment selection, sequencing and the increasingly critical role of genomic testing ⏯️ On demand now: https://lnkd.in/eAf2_-8z

Market Highlight: The immuno-oncology (IO) market is projected to grow to $154 billion by 2030. ME Therapeutics is positioned to address the unmet need with innovative therapies targeting immune suppression in cancer. Stay tuned for updates on our groundbreaking research. https://lnkd.in/effQ7kG4 #CancerResearch #BioTech #HealthcareInnovation #ImmunoOncology #InvestmentOpportunity #MarketTrends #InnovativeMedicine #MedicalScience #TumourResearch

🚨BREAKING NEWS!🚨   With the FDA's recent fast track designation for Carisma Therapeutics' CT-0525, a revolutionary CAR-Monocyte cellular therapy, the potential for macrophage-directed therapies to address unmet needs in treating HER2-overexpressing solid tumors has never been more evident.   And guess what? 𝗖𝗮𝗿𝗶𝘀𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 is on the speaker faculty for the 6th Macrophage-Directed Therapies Summit!🔥   This is a timely opportunity to shake hands with Bindu Varghese (from 𝗖𝗮𝗿𝗶𝘀𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀), who will be presenting on "Engineering Myeloid Cells for Cancer - Ex Vivo & In Vivo Approaches."   📖𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 - https://ter.li/9vo845    🎟️𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼 𝘀𝗲𝗰𝘂𝗿𝗲 $𝟵𝟬𝟬 𝗶𝗻 𝘀𝗮𝘃𝗶𝗻𝗴𝘀 - https://ter.li/t2kq70   Now's your chance to join this exclusive forum, dedicated to unraveling complex macrophage biology, accelerating novel target discovery, and driving clinical proof of concept to unleash the blockbuster potential of macrophage therapeutics.   Plus, seize our 𝗴𝗿𝗼𝘂𝗽 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 𝟮𝟬% 𝗼𝗳𝗳! Don't let this transformative event pass you by, especially with the space looking incredibly promising! #𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀𝗦𝘂𝗺𝗺𝗶𝘁

Exciting news in the field of drug repurposing! A recent preclinical study has shown that an FDA-approved antidepressant could be a potential treatment for glioblastoma, a currently incurable brain cancer. This innovative approach highlights the power of drug repurposing in offering faster, cost-effective solutions by leveraging existing treatments for new therapeutic uses. As we continue to explore novel applications for approved drugs, we may unlock new hope for patients battling some of the toughest diseases, including PolG disorders and other mitochondrial diseases. Read more about this breakthrough here: https://lnkd.in/d3GKS76w #DrugRepurposing #Glioblastoma #CancerResearch #Biotech #Innovation

Curious about how our Carcino3D™ technology works? At Carcinotech Ltd, we're dedicated to accelerating the development of cancer therapeutics. Our platform enables drug developers to access physiologically and genetically relevant models much earlier in the drug development process, bypassing the need for traditional organoid and PDX models. This streamlines R&D and pre-clinical stages, ultimately bringing treatments to market faster. Watch our video to learn more about our tumour development process. #Oncology #DrugDiscovery #CancerResearch

Precision, targeted, selective—these are words that undergird the latest R&D efforts for the cancer therapeutics industry. In this Sejelas CEO Interview series, we hear from Andy Parker, the CEO of Step Pharma. The team has turned a human genetic observation into dencatistat, the first selective CTPS1 inhibitor to enter clinical development, with signs of clinical activity in Phase I. Read the full article here: https://lnkd.in/gfp4pddH #biotech #oncology #CTPS1 #therapeutics #sejelas #ceo #interviewseries

SFBN Feed: 23andMe Launches New Genetic Reports on Common Forms of Cancer https://lnkd.in/geN4PZTd 23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe 23andMe customers can now gain deeper [...] #BayArea #SanFrancisco #Biotech #Lifescience #News